- Research article
- Open Access
Effects of rasagiline, its metabolite aminoindan and selegiline on glutamate receptor mediated signalling in the rat hippocampus slice in vitro
© Dimpfel and Hoffmann; licensee BioMed Central Ltd. 2011
- Received: 21 July 2010
- Accepted: 21 February 2011
- Published: 21 February 2011
Rasagiline, a new drug developed to treat Parkinson's disease, is known to inhibit monoamine oxidase B. However, its metabolite R-(-)-aminoindan does not show this kind of activity. The present series of in vitro experiments using the rat hippocampal slice preparation deals with effects of both compounds on the pyramidal cell response after electric stimulation of the Schaffer Collaterals in comparison to selegiline, another MAO B inhibitor.
Stimulation of the Schaffer Collaterals by single stimuli (SS) or theta burst stimulation (TBS) resulted in stable responses of pyramidal cells measured as population spike amplitude (about 1 mV under control SS conditions or about 2 mV after TBS).
During the first series, this response was attenuated in the presence of rasagiline and aminoindan-to a lesser degree of selegiline-in a concentration dependent manner (5-50 μM) after single stimuli as well as under TBS. During oxygen/glucose deprivation for 10 min the amplitude of the population spike breaks down by 75%. The presence of rasagiline and aminoindan, but rarely the presence of selegiline, prevented this break down. Following glutamate receptor mediated enhancements of neuronal transmission in a second series of experiments very clear differences could be observed in comparison to the action of selegiline: NMDA receptor, AMPA receptor as well as metabotropic glutamate receptor mediated increases of transmission were concentration dependently (0,3 - 2 μM) antagonized by rasagiline and aminoindan, but not by selegiline. On the opposite, only selegiline attenuated k ainate receptor mediated increases of excitability. Thus, both monoamino oxidase (MAO) B inhibitors show attenuation of glutamatergic transmission in the hippocampus but interfere with different receptor mediated excitatory modulations at low concentrations.
Since aminoindan does not induce MAO B inhibition, these effects must be regarded as being independent from MAO B inhibition. The results provide strong evidence for a neuroprotective activity of rasagiline and aminoindan in concert with an extended clinical indication into the direction of other diseases like Alzheimer's disease or stroke.
- Pyramidal Cell
- AMPA Receptor
- Metabotropic Glutamate Receptor
Rasagiline (N-propargyl-1-(R)-aminoindan) and selegiline are drugs prescribed for the treatment of Parkinson's disease. Both are believed to act by inhibition of monoamine oxidase B (MAO B). However, both are metabolized in a different way: rasagiline gives rise to aminoindan, a compound reported to have neuroprotective capabilities of its own, whereas selegiline gives rise to the neurotoxic metabolite methamphetamine [1, 2]. Similar electropharmacograms obtained by quantitative brain field potential analysis were obtained from freely moving rats in the presence of rasagiline and its metabolite aminoindan (not inhibiting monoamine oxidase B). Selegiline-on the other hand-produced a time dependent biphasic action presumably due to the action of its active metabolites . Available evidence suggests an additional mechanism of action for these drugs independently from MAO B inhibition.
For example, a neuroprotective action unrelated to MAO inhibition has been reported by  for rasagiline as well as for its major metabolite 1-(R)-aminoindan . For review of neuroprotective effects of rasagiline and aminoindan see . But again, no final mechanism has been reported to explain the proposed neuroprotective action. There is solid evidence of an involvement of glutamatergic transmission in neuroprotection. This calls for an experimental setup to dissect the possible interference of these compounds within the glutamatergic system. To our knowledge, no neurophysiological techniques have been applied up to now to characterize the effects of these compounds on glutamatergic transmission in the hippocampus. This model should be suitable since the communication between Schaffer-Collaterals and the hippocampal pyramidal cells takes place by using glutamate as transmitter.
The hippocampus slice preparation is a validated model for direct analysis of interaction of substances with living neuronal tissue [7, 8]. Due to the preservation of the three dimensional structure of the hippocampus, drug effects on the excitability of pyramidal cells can be studied in a unique manner. Electric stimulation of Schaffer Collaterals leads to release of glutamate resulting in excitation of the postsynaptic pyramidal cells. The result of the electrical stimulation can be recorded as a so-called population spike (pop-spike). The amplitude of the resulting population spike represents the number of recruited pyramidal cells and relates to the extent of glutamatergic transmission. The advantage of the model not only consists in the possibility of physiological recording in vitro during 8 hours but also to modify the excitability of the system in order to create pathophysiological conditions like transient oxygen and glucose deprivation (OGD) .
The first part of the present investigation aimed at the characterization of the effects of rasagiline and its metabolite aminoindan in comparison to selegiline on glutamatergic transmission within a physiological environment and under pathophysiological conditions. The principle of the second part of the investigation was to use the enhancement of the pyramidal cell response (increased amplitudes of population spike) in the presence of highly specific and selective agonists of different glutamate receptors as a challenge. Accordingly, these responses were followed in the presence of several concentrations of rasagiline, aminoindan and selegiline. This approach should reveal great similarities between rasagiline and aminoindan on one side and a great difference to the action of selegiline on the other side.
Hippocampus slices were obtained from 43 adult male Sprague-Dawley rats (Charles River Wiga, Sulzbach, Germany). Rats were kept under a reversed day/night cycle for 2 weeks prior start of the experiments, to allow recording of in vitro activity from slices during the active phase of their circadian rhythm [10, 11]. Animals were exsanguinated under ether anaesthesia, the brain was removed and the hippocampal formation was isolated under microstereoscopic sight. The midsection of the hippocampus was fixed to the table of a vibrating microtome (Rhema Labortechnik, Hofheim, Germany) using a cyanoacrylate adhesive, submerged in chilled bicarbonate-buffered saline (artificial cerebrospinal fluid (ACSF): NaCl: 124 mM, KCl: 5 mM, CaCl2: 2 mM, MgSO4: 2 mM, NaHCO3: 26 mM, glucose: 10 mM, and cut into slices of 400 μm thickness. All slices were pre-incubated for at least 1 h in Carbogen saturated ACSF (pH 7.4) in a pre-chamber before use .
TEVA Pharma GmbH
Sigma-Aldrich Chemie GmbH
CH.B: 0096 BN/01
a) Neurophysiological evidence for neuroprotective effects
b) Functional interference with NMDA receptor activation
Similar results were obtained in the presence of theta burst stimulation. Presence of ACBD in the superfusion medium increased the amplitude to 3173 μV. Rasagiline at a concentration of 5 μM attenuated the ACBD-induced signal down to 2074 μV (about control value). A statistically significant difference to ACBD-induced values was obtained at the very low concentration of 300 nM of rasagiline and aminoindan (p < 0.01). Thus, a concentration dependent attenuation of NMDA receptor induced increases of population spike amplitudes was recognized. Nearly identical results were seen in the presence of aminoindan (s. Figure 4). On the opposite, virtually no effect could be seen in the presence of selegiline up to a concentration of 5 μM. Thus, a clear difference could be observed between rasagiline and aminoindan on one site and selegiline on the other side with respect to functional antagonism of NMDA glutamate receptor stimulation.
c) Functional interference with AMPA receptor activation
Statistically significant differences to the effect of fluorowillardiine were observed with 2.5 μM of rasagiline (p < 0.02) and aminoindan (p < 0.01). Similar results were obtained in the presence of theta burst stimulation. Fluorowillardiine increased the amplitude to 2873 μV. Rasagiline at a concentration of 5 μV attenuated the fluorowillardiine-induced signal to a control value of 1950 μV. A statistically significant difference to fluorowillardiine-induced values was obtained at the very low concentration of 1 μM of rasagiline (p < 0.05).
Even stronger effects were seen in the presence of aminoindan (s. Figure 2). Aminoindan attenuated the amplitude of the population spike from 2888 μV down to 1152 μV, which is far beyond the control values. Statistical significance in comparison to AMPA receptor stimulation was obtained already at 1 μM of aminoindan. Thus, a concentration dependent attenuation of AMPA receptor induced increases of population spike amplitudes was recognized for rasagiline and even more for its metabolite aminoindan. On the opposite, virtually no effect could be seen in the presence of selegiline up to a concentration of 5 μM. Thus, a clear difference could be observed between rasagiline and aminoindan on one site and selegiline on the other side with respect to functional antagonism also of AMPA glutamate receptor stimulation.
d) Functional interference with Kainate receptor activation
Amplitudes of population spike
Theta Burst Stimulus
RS-ATPA 0.05 μM
-1904.2 ± 55.4
-3054.5 ± 42.2
+ Rasagiline 5.00 μM
-1789.0 ± 54.6 n.s
-2998.5 ± 108.3 n.s
+ Aminoindan 5.00 μM
-1946.1 ± 58.8 n.s
-2850.8 ± 92.1 n.s
+ Selegiline 2.50 μM
-1616.1 ± 37.8 p < 0.01
-2531.3 ± 136.4 p < 0.01
+ Selegiline 5.00 μM
-1256.7 ± 53.2 p < 0.01
-2133.6 ± 48.4 p < 0.01
e) Functional interference with metabotropic glutamate receptor activation
The rat hippocampal in vitro slice preparation has been used under physiological and pathophysiological conditions. Two monoamine oxidase B inhibitors (rasagiline and selegiline) and one compound lacking monoamine oxidase B inhibition (aminoindan) have been compared with respect to their ability to attenuate glutamatergic transmission represented by decreasing responses of pyramidal cells to electric stimulation. This result is interpreted to represent functional neuroprotection against massive glutamatergic excitation.
Since simulation of ischemic conditions by oxygen-glucose deprivation (OGD) likewise resulted in showing that rasagiline and aminoindan prevented the breakdown of excitability, these effects probably also relate to neuroprotection (for selegiline this could be shown only to a minor degree). The term neuroprotection usually is taken to describe effects of drugs which might result in disease modifying actions during the course of Alzheimer's or Parkinson's illness. With respect to the latter, better neuroprotective and neurorestorative actions have been described for rasagiline in comparison to selegiline against lactacystin-induced nigrostriatal dopaminergic degeneration . Also in a tissue culture model using PC12 cells under oxygen-glucose deprivation, rasagiline was clearly more effective than selegiline . In addition, these authors could show that the neuroprotective effects of selegiline were blocked by its metabolite l-methamphetamine whereas aminoindan added to the effects of rasagiline. Taken together, all these findings suggest that the aminoindan moiety might be more important for neuroprotection than the propargyl moiety as suspected earlier . Our results are therefore in line with earlier preclinical evidence for a neuroprotective action of rasagiline and its metabolite aminoindan. The functional impairment of glutamate dependent transmission obviously is not dependent on inhibition of monoamine oxidase B. However, a link between indirect inhibition of monoamine oxidase B and blockade of glyceraldehyde-3-phosphate dehydrogenase has recently been reported, which could also serve as an explanation for neuroprotective effects of rasagiline, selegiline and aminoindan .
The second part of the present investigation provides solid evidence that both rasagiline and selegiline interact functionally with glutamatergic receptor mediated transmission in addition to their known effects on MAO B, but by a different mechanism of action. The effects must be independent of the enzyme inhibition for the following reasons: firstly, aminoindan does not inhibit MAO B; secondly, both MAO inhibitors-rasagiline and selegiline-develop different receptor-mediated functional consequences within the glutamatergic system. This implicates that rasagiline and its metabolite aminoindan probably develop clinical properties different from that of selegiline.
A hypothesis exists that particular glutamate receptors of the N-methyl-D-aspartate type are over-activated in a tonic rather than a phasic manner, which under chronic conditions leads to neuronal damage . Another clinical implication could be suspected from the combined attenuation of NMDA and AMPA receptor dependent effects: simultaneous administration of sub-threshold dosages of NMDA and AMPA antagonists had a positive influence on the development of L-dopa induced dyskinesias in rats and monkeys . These data are corroborated by earlier findings showing glutamate super sensitivity in the putamen of Parkinson patients treated chronically with L-dopa . A common disadvantage of currently available rather unselective NMDA receptor antagonists is the occurrence of adverse effects like hallucinations . Therefore, rasagiline and its metabolite aminoindan, which do not induce such side effects, but not selegiline with methamphetamine as its metabolite, should have a positive effect on motor fluctuations in Parkinson patients.
With respect to the involvement of metabotropic glutamate receptors in Parkinson's disease there is evidence that they are involved in the pathologically altered circuitry in the basal ganglia. Several antagonists at this receptor alleviated L-dopa induced dyskinesia in 6-OH DA-lesioned rats . Spontaneous firing of neurons in primate pallidum was increased by metabotropic glutamate receptor agonist DHPG and decreased by selective antagonists , which is in line with our results. Since glutamatergic input from the subthalamic nucleus shows over-activity during the disease, antagonists very well could compensate for this.
Taking the effects of rasagiline and aminoindan together, not only neuroprotective effects could be measured but attenuation of NMDA, AMPA and metabotropic receptor mediated over-excitability of the glutamatergic system, also motor complications in Parkinson's disease-induced by imbalance of the glutamatergic system-should be ameliorated by a monotherapy with rasagiline. In addition, the newly discovered mechanism of action of rasagiline and aminoindan should be considered in the light of an extension of the clinical indication i.e. to treat Alzheimer's disease (for relation between Alzheimer's disease and glutamatergic system [37, 38]. Last not least, over-activation of the glutamatergic system also is one of the consequences during stroke, amyotropic lateral sclerosis, Huntington's disease and neuropathic pain . It remains to be tested if pharmacological intervention by rasagiline and its metabolite aminoindan provides a valuable therapeutic strategy for treatment of these diseases in addition to treatment of Parkinson's disease.
We greatly appreciate the experimental work as well as the data documentation performed by Mrs. Leoni Schombert. Mrs. Ingrid K. Keplinger-Dimpfel is acknowledged for her engagement in quality control.
- Bar-Am O, Amit T, Youdim MBH: Contrasting neuroprotective and neurotoxic actions of respective metabolites of anti-Parkinson drugs rasagiline and selegiline. Neuroscience Lett. 2004, 355: 169-172. 10.1016/j.neulet.2003.10.067.View ArticleGoogle Scholar
- Bar-Am O, Amit T, Youdim MBH: Aminoindan and hydroxyaminoindan, metabolites of rasagiline and ladostigil, respectively, exert neuroprotective properties in vitro. J Neurochem. 2007, 103: 500-8. 10.1111/j.1471-4159.2007.04777.x.View ArticlePubMedGoogle Scholar
- Dimpfel W, Hoffmann JA: Electropharmacograms of Rasagiline, Its Metabolite Aminoindan and Selegiline in the Freely Moving Rat. Neuropsychobiol. 2010, 62: 213-220. 10.1159/000319947.View ArticleGoogle Scholar
- Youdim MB, Wadia A, Tatton W, Weinstock M: The anti-Parkinson drug rasagiline and its cholinesterase inhibitor derivatives exert neuroprotection unrelated to MAO inhibition in cell culture and in vivo. Ann N Y Acad Sci. 2001, 939: 450-8. 10.1111/j.1749-6632.2001.tb03656.x.View ArticlePubMedGoogle Scholar
- Bar-Am O, Winreb O, Amit T, Youdim MBH: The neuroprotective mechanism of 1-(R))-aminoindan, the major metabolite of the anti-Parkinsonian drug rasagiline. J Neurochem. 2009, 112: 113-7.Google Scholar
- Mandel S, Weinreb O, Amit T, Youdim MBH: Mechanism of neuroprotective action of the anti-Parkinson drug rasagiline and its derivatives. Brain Res Rev. 2005, 48: 379-87. 10.1016/j.brainresrev.2004.12.027.View ArticlePubMedGoogle Scholar
- Lynch G, Schubert P: The use of in-vitro brain slices for multidisciplnary studies of synaptic function. Ann Rev Neurosci. 1980, 3: 1-22. 10.1146/annurev.ne.03.030180.000245.View ArticlePubMedGoogle Scholar
- Dingledine R: Brain Slices. Plenum Press New York, London. 1984Google Scholar
- Zhang H, Schools GP, Lei T, Wang W, Kimelberg HK, Zhou M: Resveratrol attenuates early pyramidal neuron excitability impairment and death in acute rat hippocampal slices caused by oxygen-glucose deprivation. Exp Neurol. 2008, 212: 44-52. 10.1016/j.expneurol.2008.03.006.PubMed CentralView ArticlePubMedGoogle Scholar
- Dimpfel W, Dalhoff B, Hofmann W, Schlüter G: Electrically evoked potentials in the rat hippocampus slice in the presence of aminophylline alone and in combination with quinolones. European Neuropsychopharmacology. 1994, 4: 151-56. 10.1016/0924-977X(94)90009-4.View ArticlePubMedGoogle Scholar
- Dimpfel W: Effect of thioctic acid on pyramidal cell responses in the rat hippocampus in vitro. Eur J Med Res. 1996, 1: 523-527.PubMedGoogle Scholar
- Dimpfel W, Spüler M, Dalhoff A, Hoffmann W, Schlüter G: Hippocampal activity in the presence of quinolones and fenbufen in-vitro. Antimicrobial Agents and Chemotherapy. 1991, 35: 1142-1146.PubMed CentralView ArticlePubMedGoogle Scholar
- Haas HL, Schaerer B, Vosmansky M: A simple perfusion chamber for the study of nervous tissue slices in vitro. J Neurosci Methods. 1979, 1: 323-5. 10.1016/0165-0270(79)90021-9.View ArticlePubMedGoogle Scholar
- Schiff SJ, Somjen GG: The Effects of Temperature on Synaptic Transmission in Hippocampal Tissue Slices. Brain Research. 1985, 345: 279-284. 10.1016/0006-8993(85)91004-2.View ArticlePubMedGoogle Scholar
- Wang ZJ, Li GM, Tang WL, Yin M: Neuroprotective effects of stearic acid against toxicity of oxygen/glucose deprivation or glutamate on rat cortical or hippocampal slices. Acta Pharmacol Sin. 2006, 27: 145-50. 10.1111/j.1745-7254.2006.00259.x.View ArticlePubMedGoogle Scholar
- Allan RD, Hanrahan JR, Hambley TW, Johnston GA, Mewett KN, Mitrovic AD: Synthesis and activity of a potent N-methyl-D-aspartic acid agonist, trans-1-aminocyclobutane-1,3-dicarboxylic acid, and related phosphonic and carboxylic acids. J Med Chem. 1990, 33: 2905-10.1021/jm00172a036.View ArticlePubMedGoogle Scholar
- Wong LA, Mayer ML, Jane DE, Watkins JC: Willardiines differentiate agonist binding sites for kainate-versus AMPA-preferring glutamate receptors in DRG and hippocampal neurons. J Neurosci. 1994, 14: 3881-PubMedGoogle Scholar
- Hawkins LM, Beaver KM, Jane DE, Taylor PM, Sunter DC, Roberts PJ: Binding of the new radioligand (S)-[3H]AMPA to rat brain synaptic membranes: effects of a series of structural analogues of the non-NMDA receptor agonist willardiine. Neuropharmacology. 1995, 34: 405-10.1016/0028-3908(94)00157-N.View ArticlePubMedGoogle Scholar
- Jane DE, Hoo K, Kamboj R, Deverill M, Bleakman D, Mandelzys A: Synthesis of willardiine and 6-azawillardiine analogs: pharmacological characterization on cloned homomeric human AMPA and kainate receptor subtypes. J Med Chem. 1997, 40: 3645-10.1021/jm9702387.View ArticlePubMedGoogle Scholar
- Matzen L, Engesgaard A, Ebert B, Didriksen M, Frølund B, Krogsgaard-Larsen P, Jaroszewski JWA: PA receptor agonists: synthesis, protolytic properties, and pharmacology of 3-isothiazolol bioisosteres of glutamic acid. J Med Chem. 1997, 40: 520-10.1021/jm9607212.View ArticlePubMedGoogle Scholar
- Clarke VR, Ballyk BA, Hoo KH, Mandelzys A, Pellizzari A, Bath CP, Thomas J, Sharpe EF, Davies CH, Ornstein PL, Schoepp DD, Kamboj RK, Collingridge GL, Lodge D, Bleakman D: A hippocampal GluR5 kainate receptor regulating inhibitory synaptic transmission. Nature. 1997, 389: 599-10.1038/39315.View ArticlePubMedGoogle Scholar
- Moldrich RX, Cheung NS, Pascoe CJ, Beart PM: Excitotoxic injury profiles of low-affinity kainate receptor agonists in cortical neuronal cultures. Eur J Pharmaocol. 1999, 378: R1-10.1016/S0014-2999(99)00456-2.View ArticleGoogle Scholar
- Kaminski RM, Banerjee M, Rogawski MA: Topiramate selectively protects against seizures induced by ATPA, a GluR5 kainate receptor agonist. Neuropharmacology. 2004, 46: 1097-10.1016/j.neuropharm.2004.02.010.View ArticlePubMedGoogle Scholar
- Irving AJ, Schofield JG, Watkins JC, Sunter DC, Collingridge GL: 1 S,3R-ACPD stimulates and L-AP3 blocks Ca2+ mobilization in rat cerebellar neurons. Eur J Pharmaocol. 1990, 186: 363-5. 10.1016/0014-2999(90)90462-F.View ArticleGoogle Scholar
- Pin JP, Duvoisin R: The metabotropic glutamate receptors: structure and functions. Neuropharmacology. 1995, 34: 1-10.1016/0028-3908(94)00129-G.View ArticlePubMedGoogle Scholar
- Knöpfel T, Kuhn R, Allgeier H: Metabotropic glutamate receptors: novel targets for drug development. J Med Chem. 1995, 38: 1417-View ArticlePubMedGoogle Scholar
- Zhu W, Xie W, Pan T, Jankovic J, Li J, Youdim MBH, Le W: Comparison of neuroprotective and neurorestorative capabilities of rasagiline and selegiline against lactacystin-induced nigrostriatal dopaminergic degeneration. J Neurochem. 2008, 105: 1970-8. 10.1111/j.1471-4159.2008.05330.x.View ArticlePubMedGoogle Scholar
- Abu-Rava S, Tabakman R, Blaugrund E, Trembovier V, Lazarovici P: Neuroprotective and neurotoxic effects of monoamine-oxydase-B inhibitors and derived metabolites under ischemia in PC12 cells. Eur J Pharmacol. 2002, 434: 109-16. 10.1016/S0014-2999(01)01548-5.View ArticleGoogle Scholar
- Bar-Am O, Weinreb O, Amit T, Youdim MBH: Regulation of Bcl-2 familiy proteins, neurotrophic factors, and APP processing in the neurorescue activity of propargylamine. FASEB J. 2005, 19: 1899-901.PubMedGoogle Scholar
- Ou X-M, Lu D, Johnson C, Chen K, Youdim MBH, Rajkowska G, Shih JC: Glyceraldehyde-3-phosphate dehydrogenase-Monoamine oxidase B-mediated cell Death-induced by Ethanol is prevented by Rasagiline and 1-R-Aminoindan. Neurotox Res. 2010, 16: 148-159. 10.1007/s12640-009-9064-7.View ArticleGoogle Scholar
- Danysz W, Parsons CG, Mobius HJ, Stoffler A, Quack G: Neuroprotective and symptomatological action of memantine relevant for Alzheimers's disease-a unified glutamatergic hypothesis o the mechanism of action. Neurotox Res. 2000, 2: 85-97. 10.1007/BF03033787.View ArticlePubMedGoogle Scholar
- Bibbiani F, Oh JD, Kielaite A, Collins MA, Smith C, Chase TN: Combined blockade of NMDA and AMPA glutamate receptors reduces levo-dopa induced motor complications in animal models of PD. Exp Neurol. 2005, 196: 422-9. 10.1016/j.expneurol.2005.08.017.View ArticlePubMedGoogle Scholar
- Calon F, Rajput AH, Hornykiewicz O, Bedard PJ, Paolo TDi: Levo-dopa induced motor complications are associated with alterations of glutamate receptors in Parkinson's disease. Neurobiol Diss. 2003, 14: 404-16. 10.1016/j.nbd.2003.07.003.View ArticleGoogle Scholar
- Hallet PJ, Standaert DG: Rationale for and use of NMDA receptor antagonists in Parkinson's disease. Pharmaco Ther. 2004, 102: 155-74. 10.1016/j.pharmthera.2004.04.001.View ArticleGoogle Scholar
- Dekundy A, Pietraszek M, Schaefer D, Cency MA, Danysz W: Effects of group I metabotropic glutamate receptors blockade in experimental models of Parkinson's disease. Brain Res Bull. 2006, 69: 318-26. 10.1016/j.brainresbull.2005.12.009.View ArticlePubMedGoogle Scholar
- Kaneda K, Tachybana Y, Imanishi M, Kita H, Shigemoto R, Nambu A, Takada M: Down-regulation of metabotropic glutamate receptor 1alpha in globus pallidus and substantia nigra of parkinson monkeys. Eur J Neurosci. 2005, 22: 3241-54. 10.1111/j.1460-9568.2005.04488.x.View ArticlePubMedGoogle Scholar
- Jacob CP, Koutsilleri E, Bartl J, Neuen-Jacob E, Arzberger T, Zander N, Ravid R, Roggendorf W, Riederer P, Grünblatt E: Alterations in expression of glutamatergic transporters and receptors in sporadic Alzheimer's disease. J Alzheimers Dis. 2007, 11: 97-116.PubMedGoogle Scholar
- Parameshwaran K, Dhanasekaran M, Suppiramaniam V: Amyloid beta peptides and glutamatergic synaptic dysregulation. Exp Neurol. 2008, 210: 7-13. 10.1016/j.expneurol.2007.10.008.View ArticlePubMedGoogle Scholar
- Planells-Cases R, Lerma J, Ferrer-Montiel A: Pharmacological interventions at ionotropic glutamate receptor complexes. Curr Pharma Des. 2006, 12: 4583-96. 10.2174/138161206778522092.View ArticleGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.